XML 238 R194.htm IDEA: XBRL DOCUMENT v3.22.4
Legal and arbitral proceedings (Details)
€ in Millions, $ in Millions
 1 Months Ended 9 Months Ended 12 Months Ended 36 Months Ended 60 Months Ended
Dec. 31, 2021
EUR (€)
plaintiff
complaint
May 14, 2013
EUR (€)
Jan. 31, 2023
Oct. 31, 2022
medical_assessment
Sep. 30, 2022
expert
Aug. 31, 2022
decision
Jul. 31, 2021
manufacturer
Feb. 28, 2021
USD ($)
Jan. 31, 2021
decision
Oct. 31, 2018
USD ($)
Sep. 30, 2017
EUR (€)
Mar. 31, 2021
proceeding
Dec. 31, 2022
EUR (€)
manufacturer
trial
case
person
children
complaint
lawsuit
claim
family
patent
Dec. 31, 2021
EUR (€)
action
Dec. 31, 2022
EUR (€)
manufacturer
trial
case
person
children
complaint
lawsuit
claim
family
Dec. 31, 2022
AUD ($)
manufacturer
trial
case
person
children
complaint
lawsuit
claim
family
Dec. 06, 2022
cancer
case
Aug. 20, 2022
ruling
May 12, 2022
ruling
Dec. 31, 2020
EUR (€)
Jul. 31, 2020
claim
family
Dec. 31, 2014
complaint
Nov. 18, 2014
patent
Apr. 30, 2013
AUD ($)
Dec. 31, 1997
EUR (€)
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Provisions for product liability risks, litigation and other € 1,374.0                       € 1,652.0 € 1,374.0 € 1,652.0         € 1,262.0          
Environmental risks € 650.0                       € 526.0 € 650.0 € 526.0         € 713.0          
Number of cases dismissed | case                                 50,000                
Number of cancers associated with dismissed cases | cancer                                 5                
Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of first instance rulings                         3   3 3   7 7            
Action for which we are defendant | Product liabilities | Minimum                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Litigation amount payable                         € 0.1   € 0.1                    
Action for which we are defendant | Product liabilities | Maximum                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Litigation amount payable                         € 0.5   € 0.5                    
Sanofi Pasteur Hepatitis B Vaccine product litigation | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of civil individual actions | lawsuit                         180   180 180                  
Number of ongoing lawsuits | lawsuit                         49   49 49                  
Taxotere product litigation in the US | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of plaintiffs | plaintiff 8,300                                                
Number of loss consortium plaintiffs | plaintiff 700                                                
Number of bellweather trial held | trial                         2   2 2                  
Taxotere mississippi attorney general litigation in the US | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Maximum penalty amount sought by plaintiffs for each violation | $                   $ 10,000                              
Zantac litigation in the US | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of plaintiffs | plaintiff 68,355                                                
Number of complaints filed | complaint 3,486                                                
Zantac litigation in Canada | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of class actions | action                           7                      
Depakine product litigation In France | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of civil individual actions | claim                         78   78 78                  
Number of people exposed | person                         131   131 131                  
Number of lawsuits ruled on merits | lawsuit                         29   29 29                  
Number of families who filed a civil claim | family                                         63        
Number of experts | expert         2                                        
Number of medical assessments | medical_assessment       6                                          
Number of people exposed who filed a request for indemnification | person                         63   63 63                  
Number of administrative proceedings | proceeding                       5                          
Depakine product litigation in Switzerland | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of people exposed | person                         16   16 16                  
Number of families who filed a civil claim | family                         10   10 10                  
Depakine product litigation in Spain | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of people exposed | children                         10   10 10                  
Number of ongoing trials | trial                         4   4 4                  
Depakine product litigation in Belgium | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of civil individual actions | complaint                         2   2 2                  
Depakine product litigation in Germany | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of civil individual actions | lawsuit                         1   1 1                  
Number of people exposed | children                         1   1 1                  
Dengvaxia product litigation in the Philippines | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of cases | case                             8                    
Ramipril Canada Patent Litigation | Action for which we are a plaintiff | Patents                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of manufacturers with marketing authorization for generic version of drug | manufacturer                         8   8 8                  
Praluent (Alirocumab)-related amgen patent litigation in the US | Action for which we are defendant | Patents                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of patent actions initially filed | complaint                                           4      
Number of patents allegedly infringed | patent                                             7    
Jevtana related patent litigation in the US | Action for which we are a plaintiff | Patents                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of patents allegedly infringed | claim                                         12        
Number of patents covering product | patent                         4                        
Number of decisions issued by the District Court | decision           2     2                                
Number of days after the completion of the post-trial briefing (in days)                         120 days                        
Jevtana related patent litigation in the US | Action for which we are a plaintiff | Patents | Commencement of major litigation [member]                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Length of trial (in days)     3 days                                            
Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Patents                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Payment of damages sought by Australian Department of Health related to the Apotex preliminary injunction, up to                         € 286.0   € 286.0                 $ 449.0  
Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Patents | Minimum                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Reduced amount of compensation claimed                         142.1   142.1 $ 223.3                  
Reduced amount of compensation claimed, interest included                         218.6   218.6 343.4                  
Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Patents | Maximum                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Reduced amount of compensation claimed                         178.4   178.4 280.2                  
Reduced amount of compensation claimed, interest included                         € 295.1   € 295.1 $ 463.6                  
Plavix Attorney General Action in Hawaii | Action for which we are defendant                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Total penalty fee incurred by defendants | $               $ 834,012,000                                  
Penalty fee incurred by Sanofi | $               $ 417,006,000                                  
Plavix related litigation in France | Action for which we are defendant                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Penalty fee incurred by Sanofi   € 40.6                                              
Payment of damages claimed by the French CNAM (French Social Security)                     € 115.8                            
340B Drug Pricing Program in the United States | Action for which we are defendant                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of other manufacturers involved in proceedings | manufacturer             3                                    
Aventis Crop Science retained liabilities | Contingencies arising from certain business divestitures                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Aggregate participation percentage of legacy companies in ACS                         76.00%                        
Infraserv Hoechst retained liabilities | Contingencies arising from certain business divestitures                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Fund reserves transferred                                                 € 57.0
Maximum amount to be reimbursed for current and future environmental expense                                                 € 143.0
Depakine Product Litigation In Ireland | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of pre-action protocol cases | case                         2   2 2                  
Number of civil claims on-going | claim                         2   2 2                  
Depakine Product Litigation In Great Britain | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of pre-action protocol cases | case                         3   3 3                  
Depakine Product Litigation In Northern Ireland | Action for which we are defendant | Product liabilities                                                  
Disclosure of Legal and Arbitral Proceedings [Line Items]                                                  
Number of pre-action protocol cases | case                         1   1 1